{"entity":{"id":"agx-148","kind":"drug","name":"AGX-148","aka":["CD39+CD103+ double-positive TIL"],"tldr":"AGX-148 is an experimental cell therapy from AgonOx made from the tumour-recognising immune cells in a patient's own tumour. It is in an early trial in solid tumours.","summary":"AGX-148 is AgonOx's lead TIL programme. AgonOx sponsors NCT05902520, a phase 1 trial of cancer-specific CD8 tumour-infiltrating lymphocytes in adults with solid tumours, listed on ClinicalTrials.gov as active and not recruiting, and a 2026 National Cancer Institute SBIR award funds its development for breast cancer.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"AgonOx","url":"https://www.agonox.com/"},{"label":"ClinicalTrials.gov: NCT05902520","url":"https://clinicaltrials.gov/study/NCT05902520"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":[],"companies":["agonox"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"AGX-148","modality":"Autologous tumour-infiltrating lymphocyte therapy","mechanism":"A patient's own CD8 tumour-infiltrating lymphocytes, enriched for the CD39-positive, CD103-positive subset that AgonOx describes as tumour-reactive, expanded and infused back.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/agx-148/","neighbours":{"technology":[{"id":"til-therapy","kind":"technology","name":"TIL therapy","route":"/technologies/til-therapy/"}],"company":[{"id":"agonox","kind":"company","name":"AgonOx","route":"/companies/agonox/"}]}}